RHÖN-KLINIKUM (ETR:RHK) Is Doing The Right Things To Multiply Its Share Price

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. Speaking of which, we noticed some great changes in RHÖN-KLINIKUM's (ETR:RHK) returns on capital, so let's have a look.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Return On Capital Employed (ROCE): What Is It?

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on RHÖN-KLINIKUM is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.031 = €45m ÷ (€1.9b - €411m) (Based on the trailing twelve months to March 2025).

Therefore, RHÖN-KLINIKUM has an ROCE of 3.1%. Ultimately, that's a low return and it under-performs the Healthcare industry average of 5.1%.

See our latest analysis for RHÖN-KLINIKUM

Above you can see how the current ROCE for RHÖN-KLINIKUM compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for RHÖN-KLINIKUM .

What Does the ROCE Trend For RHÖN-KLINIKUM Tell Us?

While there are companies with higher returns on capital out there, we still find the trend at RHÖN-KLINIKUM promising. The figures show that over the last five years, ROCE has grown 76% whilst employing roughly the same amount of capital. So our take on this is that the business has increased efficiencies to generate these higher returns, all the while not needing to make any additional investments. The company is doing well in that sense, and it's worth investigating what the management team has planned for long term growth prospects.

The Bottom Line On RHÖN-KLINIKUM's ROCE

As discussed above, RHÖN-KLINIKUM appears to be getting more proficient at generating returns since capital employed has remained flat but earnings (before interest and tax) are up. Given the stock has declined 27% in the last five years, this could be a good investment if the valuation and other metrics are also appealing. That being the case, research into the company's current valuation metrics and future prospects seems fitting.

While RHÖN-KLINIKUM looks impressive, no company is worth an infinite price. The intrinsic value infographic for RHK helps visualize whether it is currently trading for a fair price.

While RHÖN-KLINIKUM isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.